Histosonics Inc. is extremely proud to have the results of our pivotal #HOPE4LIVER Trials data published today in Radiology. The trials met co-primary endpoints for technical success and safety, enabling histotripsy's quick adoption into clinical practice. businesswire.com/news/home/2024…

Histosonics Inc. is proud to have results from the pivotal #HOPE4LIVER Trials presented at @CIO2024 by Mishal Mendiratta-Lala MD, University of Michigan. #HOPE4LIVER Trial results were recently published in the journal Radiology. lnkd.in/eue6rUn8

HistoSonics, Inc. is excited to participate in #ASTRO2024 September 29th - October 1st in Washington, DC. with our now FDA cleared Edison Histotripsy System using non-invasive sonic beam therapy to destroy targeted tumors. "Meet Edison" at Booth #2709

HistoSonics is excited to announced that we have been awarded an exclusive ongoing contract with the Dept. of Veterans Affairs for up to $90 million for VA hospitals to acquire novel, non-invasive Edison Histotripsy Systems for US Veterans. #Veterans businesswire.com/news/home/2024…

Histosonics Inc. , Inc. is extremely proud to celebrate Veterans Day alongside our partner FSD as we honor those men and women who serve and who have served the United States of America with honor, courage and commitment.

Histosonics Inc. is proud to announce the first patients were enrolled in our novel prospective master protocol study, called BOOMBOX, designed to evaluate the real-world use of histotripsy for treatment of liver tumors. businesswire.com/news/home/2024…

Interventional Radiology and Ohio State Wexner Medical Center Urology Dept. teams, led by Mina S. Makary, MD and Eric A. Singer, MD, MA, MS, FACS, FASCO, recently became the first in Ohio to perform histotripsy. The non-invasive procedure could significantly improve outcomes, providing world-class care while improving quality of life.

@HistoSonics is excited to announce the first patients have been treated as part of our feasibility study, named the GANNON trial, designed to evaluate the safety of the Edison System & histotripsy to non-invasively destroy inoperable pancreatic tumors. businesswire.com/news/home/2024…

Histosonics Inc. also is excited to have Brian Fuller, MBA, Senior Director of Clinical Operations, from #ProvidenceMissionHospital to describe the business experience of a successful histotripsy breakfast program at #siovegas this week. #Histotripsy

Histosonics Inc. , Inc. is honored to attend #siovegas this week in Las Vegas and to have Christos Georgiades MD, PhD. and Bruno Odisio MD, PhD. lead an interactive "Histotripsy Year In Review" panel Saturday, February 1st in the Bronze Room from 7:15 am - 8:45 am. #Histotripsy

Histosonics Inc. is hosting Jim Porter MD. and Arun Rai MD. on March 18th at 7:00 pm ET for "New Frontiers for Histotripsy" to share their experience with histotripsy use for the destruction of kidney tumors as part of the #HOPE4KIDNEY Trial. Register here: lnkd.in/ebkpFg3f

Histosonics Inc. is proud to partner with FSD to announce the first Veterans Affairs Hospital to acquire the Edison System is the VA Houston Michael E. Debakey VA Hospital. Proud to partner with the VA for our Veterans! #InnovationPartners #histotripsy vimeo.com/1051601355?sha…

Histosonics Inc. wins NVCA’s 2025 Startup Innovator Award! From groundbreaking research at University of Michigan to redefining tumor treatment with sonic beam therapy, HistoSonics is changing the game. We’re proud to celebrate their impact at the NVCA Leadership Awards Dinner on June 5! 🔗:

Histosonics Inc. is extremely proud to be recognized by Fast Company as "2025's Most Innovative Medical Device Company" in the world! Our Histo team, our clinical and hospital partners all share in this award and deserve recognition for fulfilling our shared patient first mission.

⁦Histosonics Inc.⁩ , Inc. is extremely proud to have our CEO and President Mike Blue named as a finalist for the ⁦⁦EY US⁩ 2025 Entreprenuer of the Year! linkedin.com/posts/histoson…

Histosonics’ Histotripsy System Demonstrates 90% Local Tumor Control at 12 Months in #HOPE4LIVER Trials. Durable local control and favorable safety profile position histotripsy as a non-invasive alternative to standard of care locoregional therapy. tinyurl.com/ytv739am

Histosonics Inc. is extremely excited for patients of BCBSM who are now covered to received histotrispy for liver tumors. businesswire.com/news/home/2025…

Histosonics Inc. is excited to announce we have been awarded early market access to the UK via the Unmet Clinical Needs Authorisation program. This milestone comes through great collaboration between HistoSonics, the NHS and UK physicians. businesswire.com/news/home/2025…

Histosonics Inc. is proud to announce the completion of patient enrollment in our pivotal#HOPE4KIDNEY trial. The trial was designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating solid kidney tumors. businesswire.com/news/home/2025…

HistoSonics Announces $2.25B Acquisition by Consortium of Top-Tier Investors “Our relentless focus as a company has been speed, scale, and the urgency to offer patients a better option than any they have today,” said CEO Mike Blue. businesswire.com/news/home/2025…